KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Share-based Compensation (2016 - 2025)

Neogenomics (NEO) has disclosed Share-based Compensation for 16 consecutive years, with $8.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 3.43% year-over-year to $8.0 million, compared with a TTM value of $41.3 million through Dec 2025, up 23.65%, and an annual FY2025 reading of $41.3 million, up 23.65% over the prior year.
  • Share-based Compensation was $8.0 million for Q4 2025 at Neogenomics, down from $10.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $12.2 million in Q2 2025 and bottomed at $2.7 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $7.3 million, with a median of $7.5 million recorded in 2023.
  • The sharpest move saw Share-based Compensation surged 356.2% in 2022, then tumbled 60.69% in 2023.
  • Year by year, Share-based Compensation stood at $10.1 million in 2021, then plummeted by 53.66% to $4.7 million in 2022, then surged by 49.9% to $7.0 million in 2023, then rose by 19.14% to $8.3 million in 2024, then dropped by 3.43% to $8.0 million in 2025.
  • Business Quant data shows Share-based Compensation for NEO at $8.0 million in Q4 2025, $10.3 million in Q3 2025, and $12.2 million in Q2 2025.